Every so often you meet a founder so sharp that every conversation lights up new pathways in your thinking and quickly deepens your grasp of their business and technology. Working with people like that is a privilege.

Introducing Agent Ultra - a step change in deep research Agent Ultra orchestrates swarms of agents to perform exhaustive research, build comprehensive lists, and answer questions requiring thousands of sources. In both evals and vibes, it's state of the art

20 years ago, I was here in New York, pitching a small startup from Europe. This week, I'm back here, once again in pitch mode, talking to friends old and new about democratizing preventive health with @Neko. I've always been obsessed with building the most amazing product possible. And with Neko, the end goal is to truly change consumer behaviour. We want as many people as possible to have access to quality preventive healthcare - not for the 1%, but for the 99%. Thank you to my co-founder Hjalmar (@HNilsonne) and to the amazing team that made our first New York clinic opening possible today.

Today we announced the Claude-led discovery of a molecular machine that we suspect could represent a new gene editing mechanism. Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is work I would have been proud to do as a PhD student. The work was done mostly, though not entirely, by Claude: our life sciences team suggested a broad area of research, Claude read through the literature and a bunch of genome data and discovered something interesting, then Claude proposed experiments to verify the discovery and our team carried them out. It’s easy to dismiss this as a one-off or curiosity, but we’ve repeatedly seen a pattern where AI performance in new intellectual domains goes from weak to superhuman in a matter of a few years. In 2023 models struggled to do math at the level of an average high-school student. In 2024 they started to do well on math competitions for the best high-schoolers in the country, in 2025 they started to solve minor open problems, in early 2026 more significant open problems, and in late 2026 they are beginning to solve the top few open problems in all of mathematics. We believe AI for biology is on a similar exponential trend. The main difference between biology and mathematics, of course, is that math can be done purely theoretically, while biology requires experimentation. Some have used this to draw the conclusion that AI’s utility in biology will be limited. We think this is wrong. As we’ve demonstrated today, humans can collaborate with AI to perform the experiments, validate key results in a few weeks and, if necessary, work with the AI to iterate on what they find. Eventually it may even be possible for Claude itself to safely perform the experiments by autonomously controlling lab equipment, with appropriate safeguards in place, but we aren’t doing that today (our lab is also a BSL1/BSL2 facility that doesn't handle materials dangerous to humans). More broadly, biomedical advancement has many stages — from fundamental biology discoveries, to translational research, to drug discovery, clinical trials, and finally the actual delivery of medicines and health care to patients. We are also interested in these later stages, but even simply accelerating the first stage of fundamental biological discoveries has the potential to speed up and broaden the entire pipeline. Improving our understanding of biology and sharpening biologists’ tools can drive forward all of the later stages, for example by identifying new drug targets, finding new therapeutic modalities, allowing for more precise measurement, and speeding up the experimental loop which itself further accelerates our understanding of biology. This will not in itself speed up clinical trial times, but if it succeeds it could greatly increase the number of promising candidates that go into the pipeline — an increase in throughput even though latency remains. In Machines of Loving Grace, I wrote about AI’s potential to “cure most diseases in 5-10 years” — a goal that sounds impossible, but one I believe is just barely possible if AI is applied to every stage of the pipeline. The first step is showing that AI can first help with, and then drive, biological discoveries. Claude’s discovery is the latest in a line of related prior work that goes back decades, beginning with systems like CRISPR, and continuing with discoveries like the bridge recombinase and VIPR in the past few years. Recently, there has been heightened interest in systems based on reverse transcriptase (RT) enzymes, the enzyme underlying the system Claude identified. And most recently, a Stanford team working independently described a novel RT system with an associated non-coding array that is in some ways similar to the one Claude found, though they are distinct systems that evolved independently from each other. I believe that we’re at the very beginning of finding such systems and developing them into powerful tools for biotechnology. I’m proud of the resources Anthropic has invested in accelerating the public benefits of AI through the life sciences, and we’re aiming both to grow our life sciences team and to work with other scientists to extend this approach to a broad range of problems. If you have a proposal for a research collaboration or are interested in joining our life sciences team, please reach out.

The data bottleneck for physical AI keeps getting smaller!! First @SkildAI showed robots learning from human videos. Then S1 learned new tasks from a single video prompt. Now S1 can keep improving through self-play without new demonstrations. Incredible work @deepakpathak @gupta_abhinav_ and Team @SkildAI! Grateful to be your partners at @lightspeedvp

I'm excited to announce @SnorkelAI's $350M Series E at $3.5B, led by @insightpartners and @S32_VC. We've grown 18x+ in the last 12 months since launching our Data-as-a-Service offering, passing $375M ARRR this week. As AI advances to superhuman capabilities, AI data & environment development must advance with it - and basic staffing and crowdsourcing approaches are not enough. AI progress now requires deep research and technology work that combines human expertise with specialized AI in compounding ways. @SnorkelAI is building the RSI data engine and frontier data lab for this next phase. We're honored to have the support of existing investors Addition, @lightspeedvp, @GreylockVC, @GVteam, P7, Factory, @WellsFargo, Walden Catalyst Ventures, and new investors @ThirdPointLLC, @MarchCPs, @BlumbergCapital, @AllegisCapital, @Frontlinevc, and @standard_vc. – @SnorkelAI started as a research project a decade ago at @StanfordAILab. Our thesis was simple: AI progress would become increasingly data-centric – and therefore data development should be studied as a true research and technology problem, not just a staffing and crowdsourcing one. Today, as AI capabilities verge on superhuman, building the data and environments to safely measure and train AI is becoming too hard for even the smartest human experts to do alone. Only humans and AI agents, collaborating together in compounding ways, can meet the accelerating needs of the frontier, and keep humans in the driver’s seat of AI progress for decades to come. At @SnorkelAI, we are building the data lab to define the shape of this new “Data 2.0” frontier, and the new paradigms of human-computer interaction needed to advance it. Our key focus is building the RSI engine for data, where specialized AI models accelerate and improve human expert output, and in turn, scaled human supervision is used to continuously evaluate and improve these models – creating a powerful compounding loop to keep pace with an accelerating RSI frontier. With this round of funding, we are also doubling down on our commitments to support data development for open benchmarking and evaluation (more news here soon!); an increasingly diverse ecosystem of general and specialized intelligence; and a path to safe, well-aligned AI built on robust training and evaluation data. Data development will guide and drive the next stages of AI – and must do so in a human-centric, AI accelerated, open, diverse, and safe way. We are excited to support this mission in the next decade of research ahead at @SnorkelAI. More thoughts here:

Pretty cool that General Motors was able to retool a car factory to make the outer shells of the Patriot missiles. They've managed to make the delivery to Lockheed just 22 days after signing the contract. (22 days!!!!! We still got it...🇺🇸🇺🇸🇺🇸) Lockheed says this work normally takes months or years for the previous supplier (General Dynamics) to fulfill. There's a strain of neoliberal thinking that says if domestic carmakers can’t compete, they should just be allowed to fail. No bailouts. Just let Japan or China make cars because of comparative advantage or whatever. Imagine if we had believed that automobile manufacturing was something to offshore. It's now clear that the argument for preserving that industrial base is not simply nostalgia for a previous bygone era. It simply is the case that you cannot improvise precision manufacturing overnight once it has disappeared.

I used Opus 5.5 to formally verify the Claude Agent SDK using Lean. A couple short prompts = 16 PRs fixing various bugs and race conditions. Video attached. TLA+ also works well. I sometimes combine Lean and TLA+ to look for issues around data flow, concurrency, and state mgmt. I don't know either language well, but Claude is excellent at both. This approach is super useful for formally modeling your code and finding bugs that a human probably wouldn't have spotted. Is formal verification the future of coding (or at least, bug finding)?